Incidence Rate of Fluoroquinolone-Resistant Gram-Negative Rod Bacteremia among Allogeneic Hematopoietic Cell Transplantation Patients during an Era of Levofloxacin Prophylaxis

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 3, 2015, Pages 539-545

  Miles Jay, Arianna ^a,b   Butler Wu, Susan ^b   Rowhani Rahbar, Ali ^b   Pergam, Steven A ^a,c,d  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c SEATTLE CANCER CARE ALLIANCE   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Fluoroquinolone resistance; Gram negative; Hematopoietic cell transplantation

Indexed keywords

LEVOFLOXACIN; ANTIINFECTIVE AGENT;

ADULT; ARTICLE; BACTEREMIA; COHORT ANALYSIS; DISEASE SEVERITY; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE SEPSIS; HEMATOPOIETIC CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; POST HOC ANALYSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; AGED; ALLOGRAFT; ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; GRAM NEGATIVE ANAEROBIC BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; TIME FACTOR;

ADULT; AGED; ALLOGRAFTS; ANTI-BACTERIAL AGENTS; BACTEREMIA; DRUG RESISTANCE, BACTERIAL; FEMALE; GRAM-NEGATIVE ANAEROBIC STRAIGHT, CURVED, AND HELICAL RODS; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INCIDENCE; LEVOFLOXACIN; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84922799442     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.12.006     Document Type: Article

References (30)

1. Mikulska M., Del Bono V., Raiola A.M., et al. Blood stream infections in allogeneic hematopoietic stem cell transplant recipients: reemergence of Gram-negative rods and increasing antibiotic resistance. Biol Blood Marrow Transplant 2009, 15:47-53.
2. Collin B.A., Leather H.L., Wingard J.R., Ramphal R. Evolution, incidence, and susceptibility of bacterial bloodstream isolates from 519 bone marrow transplant patients. Clin Infect Dis 2001, 33:947-953.
3. Bock A.M., Cao Q., Ferrieri P., et al. Bacteremia in blood or marrow transplantation patients: clinical risk factors for infection and emerging antibiotic resistance. Biol Blood Marrow Transplant 2013, 19:102-108.
4. Gooley T.A., Chien J.W., Pergam S.A., et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. NEngl J Med 2010, 363:2091-2101.
5. Tomblyn M., Chiller T., Einsele H., et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009, 15:1143-1238.
6. National Comprehensive Cancer Network. Prevention and treatment of cancer related infections. Version 2.2014. Available at: Accessed October2014. http://www.nccn.org.
7. Girmenia C., Menichetti F. Neutropenia and Infections Epidemiology and Prevention of Infectious Complications. Eur Oncol Haematol 2011, 7(4):270-277.
8. Gafter-Gvili A., Fraser A., Paul M., et al. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev 2012, 1:CD004386.
9. Guthrie K.A., Yong M., Frieze D., et al. The impact of a change in antibacterial prophylaxis from ceftazidime to levofloxacin in allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2010, 45:675-681.
10. Therriault B.L., Wilson J.W., Barreto J.N., Estes L.L. Characterization of bacterial infections in allogeneic hematopoietic stem cell transplant recipients who received prophylactic levofloxacin with either penicillin or doxycycline. Mayo Clin Proc 2010, 85:711-718.
11. Green M.L., Leisenring W., Stachel D., et al. Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012, 18:1687-1699.
12. Simondsen K.A., Reed M.P., Mably M.S., et al. Retrospective analysis of fluoroquinolone prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation. JOncol Pharm Pract 2013, 19:291-297.
13. Lautenbach E., Metlay J.P., Bilker W.B., et al. Association between fluoroquinolone resistance and mortality in Escherichia coli and Klebsiella pneumoniae infections: the role of inadequate empirical antimicrobial therapy. Clin Infect Dis 2005, 41:923-929.
14. Tatro J.B. Endogenous antipyretics. Clin Infect Dis 2000, 31(Suppl 5):S190-S201.
15. Becnel Boyd L., Maynard M.J., Morgan-Linnell S.K., et al. Relationships among ciprofloxacin, gatifloxacin, levofloxacin, and norfloxacin MICs for fluoroquinolone-resistant Escherichia coli clinical isolates. Antimicrob Agents Chemother 2009, 53:229-234.
16. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement. CLSI document M100-S22. Wayne, PA: Clinical and Laboratory Standards Institute; 2012.
17. Parimon T., Au D.H., Martin P.J., Chien J.W. Arisk score for mortality after allogeneic hematopoietic cell transplantation. Ann Intern Med 2006, 144:407-414.
18. Kern W.V., Klose K., Jellen-Ritter A.S., et al. Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis 2005, 24:111-118.
19. Macesic N., Morrissey C.O., Cheng A.C., et al. Changing microbial epidemiology in hematopoietic stem cell transplant recipients: increasing resistance over a 9-year period. Transpl Infect Dis 2014, 16:887-896.
20. Simmons S., Bryson C., Porter S. "Scrub the hub": cleaning duration and reduction in bacterial load on central venous catheters. Crit Care Nurs Q 2011, 34:31-35.
21. Bleasdale S.C., Trick W.E., Gonzalez I.M., et al. Effectiveness of chlorhexidine bathing to reduce catheter-associated bloodstream infections in medical intensive care unit patients. Arch Intern Med 2007, 167:2073-2079.
22. Galpern D., Guerrero A., Tu A., et al. Effectiveness of a central line bundle campaign on line-associated infections in the intensive care unit. Surgery 2008, 144:492-495. discussion 495.
23. Sannoh S., Clones B., Munoz J., et al. Amultimodal approach to central venous catheter hub care can decrease catheter-related bloodstream infection. Am J Infect Control 2010, 38:424-429.
24. Mielcarek M., Furlong T., Storer B.E., et al. Efficacy and safety of lower-dose glucocorticoids for initial treatment of acute graft-versus-host disease: a randomized controlled trial. Blood 2013, 122:703.
25. Bucaneve G., Micozzi A., Menichetti F., et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. NEngl J Med 2005, 353:977-987.
26. Cullen M., Steven N., Billingham L., et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. NEngl J Med 2005, 353:988-998.
27. Robicsek A., Jacoby G.A., Hooper D.C. The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect Dis 2006, 6:629-640.
28. Ibrahim E.H., Sherman G., Ward S., et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000, 118:146-155.
29. Leibovici L., Shraga I., Drucker M., et al. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. JIntern Med 1998, 244:379-386.
30. Hakki M., Limaye A.P., Kim H.W., et al. Invasive Pseudomonas aeruginosa infections: high rate of recurrence and mortality after hematopoietic cell transplantation. Bone Marrow Transplant 2007, 39:687-693.